Market closedNon-fractional

Arcutis Biotherapeutics/ARQT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Ticker

ARQT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Westlake Village, United States

Employees

296

ARQT Metrics

BasicAdvanced
$1.1B
Market cap
-
P/E ratio
-$2.66
EPS
1.18
Beta
-
Dividend rate
$1.1B
1.18
9.894
9.322
91.572
91.908
-6.52%
-28.62%
-119.24%
7.571
5.05
5.19
-4.055
1,545.18%
-53.12%
-8.49%

What the Analysts think about ARQT

Analyst Ratings

Majority rating from 7 analysts.
Buy

ARQT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-71.31% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$50M
266.67%
Net income
-$35M
-46.68%
Profit margin
-71.31%
-85.46%

ARQT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 56.16%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.16
-$0.73
-$0.72
-$0.32
-
Expected
-$1.25
-$0.86
-$0.78
-$0.73
-$0.57
Surprise
-7.21%
-14.87%
-7.10%
-56.16%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Arcutis Biotherapeutics stock?

Arcutis Biotherapeutics (ARQT) has a market cap of $1.1B as of July 23, 2024.

What is the P/E ratio for Arcutis Biotherapeutics stock?

The price to earnings (P/E) ratio for Arcutis Biotherapeutics (ARQT) stock is 0 as of July 23, 2024.

Does Arcutis Biotherapeutics stock pay dividends?

No, Arcutis Biotherapeutics (ARQT) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next Arcutis Biotherapeutics dividend payment date?

Arcutis Biotherapeutics (ARQT) stock does not pay dividends to its shareholders.

What is the beta indicator for Arcutis Biotherapeutics?

Arcutis Biotherapeutics (ARQT) has a beta rating of 1.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Arcutis Biotherapeutics stock

Buy or sell Arcutis Biotherapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing